Paediatrics

Childhood Cancer Awareness Month
#Cancer research #Childhood cancer #Clinical trials #Oncology #Paediatrics

Five key studies into drugs for childhood cancers

DDW's Diana Spencer highlights five key clinical studies taking a new therapeutic approach to childhood cancers. Over 100 subtypes of childhood cancer exist today and it represents the most common cause of disease-related death in children. However, despite the fact that children’s response to adult cancer drugs is often poor,… Read More

#Cancer Research #Exclusive Content

#Cancer research #Funding #Investment #Oncology #Paediatrics

$4.3 million awarded to advance transcription factor drugs

Talus Bio has received $4.3 million in new grants from the National Institutes for Health (NIH) and the Washington State Andy Hill CARE Fund to advance its paediatric cancer therapeutics. The Seattle-based company received two grants totalling $2.3M from the CARE Fund to fuel the discovery of new transcription factor… Read More

#Business & Investment #News

Child with respiratory syncytial virus
#Immunology / Virology & Vaccines #Meissa Vaccines #Paediatrics #Phase I trial #Respiratory syncytial virus

‘Compelling’ data for paediatric live attenuated RSV vaccine

A new respiratory syncytial virus (RSV) vaccine candidate has achieved positive safety and immunogenicity results in a Phase I clinical study of RSV-naïve participants between the ages of six and 36 months. MV-012-968 is being developed by Meissa Vaccines as a needle-free, adjuvant-free vaccine to protect… Read More

#News

Paediatric medicine concept
#Drug development #EMA #FDA #Paediatrics #Regulatory

What recent paediatric guidelines mean for drug developers 

Justin Hay, Senior Director, Amy Cheung Senior Director of Integrated Drug Development, and Patrick Loebs Director, at Certara, examine recent changes in paediatric guidelines and how they affect drug development projects.   It has been a very busy period recently for paediatric drug development with the release of many guidance documents… Read More

#Regulatory

Drug discovery illustration
#Covid-19 #Drug repositioning #Drug repurposing #Events #Paediatrics #Pharmacology #Rare disease #World Congress of Basic & Clinical Pharmacology

Drug repurposing: The benefits, risks and what we learned from Covid-19

What are benefits of drug repurposing and why do clinical drug trials so often fail? Diana Spencer summarises the key messages from the ‘Drug Repurposing: Challenges and Opportunities’ Symposium held at the 19th World Congress of Basic & Clinical Pharmacology (WCP) 2023. The Drug Repurposing symposium at WCP 2023 was… Read More

#Exclusive Content

Baby on a respirator - RSV
#AstraZeneca #FDA #Monoclonal antibodies #Paediatrics #Respiratory syncytial virus

Monoclonal antibody to prevent RSV in babies approved in US

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season. The drug is also approved in children up to 24 months of age who… Read More

#News #Regulatory

bone cancer
#Bone cancer #Childhood cancer #Funding #Osteosarcoma #Paediatrics

$1.5 million awarded for osteosarcoma research 

CureSearch for Children’s Cancer has awarded a $1.5 million grant to Dr Patrick Grohar of Children’s Hospital of Philadelphia to develop a new targeted treatment approach for paediatric osteosarcoma, an aggressive form of bone cancer.    The award – the Fight Osteosarcoma Together Super Grant – is a… Read More

#News

Dravet syndrome
#Biotherapeutics #Dravet syndrome #Paediatrics

Bloom Science completes enrolment in Dravet Syndrome trial

Bloom Science, a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis, has completed enrolment in all four cohorts of healthy adult participants as part of its Phase I clinical trial.   Bloom is developing BL-001 for Dravet… Read More

#News

siRNA
#FDA #Orphan drugs #Paediatrics #Rare disease #siRNA #SiSaf

Therapy for rare skeletal disorder granted orphan status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to SiSaf’s small interfering RNA (siRNA) therapeutic for skeletal disorder Autosomal Dominant Osteopetrosis Type 2 (ADO2). In addition, due to the serious manifestations of this rare disease in children, SIS-101-ADO has been granted Rare Pediatric Disease Designation for… Read More

#News #Regulatory

Cancer cells
#AACR 2023 #Cancer research #Oncology #Paediatrics #Phase I trial #Solid tumours

Combo therapy may benefit some paediatric cancer patients

A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in paediatric patients with solid tumours exhibiting DNA replication stress and/or DNA repair deficiencies, according to new data. The results from the Phase I portion of the Phase I/II… Read More

#Cancer Research #News

Medical researcher
#Funding #Genetics / genomics #Investment #Paediatrics #Rare disease #SynaptixBio

‘Virtual’ biotech targets R&D funding on rare disease therapy

UK biotech firm SynaptixBio has secured £13.2 million to fund its development of the world’s first treatment for TUBB4A-related leukodystrophy, a rare, incurable and deadly disease. The company successfully raised £11.05m in its latest funding round to add to the £2.125m of seed funding from the last two years. It… Read More

#Business & Investment #News

#Brain cancer #Cancer research #Childhood cancer #Clinical trials #Paediatrics

CureSearch to fund Phase I clinical trial for paediatric brain cancer 

CureSearch for Children’s Cancer, a national non-profit with a mission to end childhood cancer by driving targeted and innovative research in an accelerated time frame, will fund a Phase I clinical trial to bring new therapies to paediatric brain cancer patients, including those with limited or no treatment options. Read More

#Cancer Research #News

Genetic engineering
#Cell and gene therapy #CNS #Gene editing #Gene therapy #Genetics / genomics #Paediatrics #Stem cells

Gene therapy for ‘childhood dementia’ shows promise

An investigational gene therapy for Sanfilippo syndrome – which leads to a form of childhood dementia – has shown promising early results in a proof-of-concept study.  The study found that four out of five patients diagnosed with Sanfilippo have continued to gain cognitive skills in line with… Read More

#Editor's Choice #News

Duchenne muscular dystrophy
#Muscular dystrophy #National Institute for Health and Care Excellence (NICE) #Paediatrics #PTC Therapeutics #Rare disease

Rare muscular dystrophy drug to be funded in England and Wales

The National Institute for Health and Care Excellence (NICE) has published its Final Guidance recommending Translarna (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales.   Translarna is the only approved treatment for patients with nonsense mutation Duchenne muscular dystrophy aged two years and older… Read More

#News #Regulatory

Stamp of approval
#European Commission #Orphan drugs #Paediatrics #Phase III trial #Regulatory #UCB

Fenfluramine approved in the EU for LGS seizures

UCB’s Fintepla (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).  It has received authorisation as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.  The approval was based on safety and… Read More

#News #Regulatory

Demyelination of neuron
#FDA #Muscular dystrophy #Paediatrics #Rare disease #SynaptixBio

Treatment for leukodystrophy could be “revolutionary”

The US Food and Drug Administration (FDA) has granted Rare Paediatric Disease (RPD) Designation to SynaptixBio’s drug candidate for TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and young children.  RPDs are designed to encourage the development of new drugs with high unmet medical needs, including… Read More

#Editor's Choice #News #Regulatory